Gene expression profiles of no- and hno-donor treated breast cancer cells: insights into tumor response and resistance pathways
Cheng, Robert Y.S.
Ridnour, Lisa A.
Heinecke, Julie L.
Kesarwala, Aparna H.
Switzer, Christopher H.
Miranda, Katrina M.
Wink, David A.
MetadataShow full item record
This item's downloads: 0 (view details)
Cited 14 times in Scopus (view citations)
Cheng, Robert Y.S. Basudhar, Debashree; Ridnour, Lisa A.; Heinecke, Julie L.; Kesarwala, Aparna H.; Glynn, Sharon; Switzer, Christopher H.; Ambs, Stefan; Miranda, Katrina M.; Wink, David A. (2014). Gene expression profiles of no- and hno-donor treated breast cancer cells: insights into tumor response and resistance pathways. Nitric Oxide 43 , 17-28
Nitric oxide (NO) synthase 2 (NOS2), a major inflammatory protein, modulates disease progression via NO in a number of pathologies, including cancer. The role of NOS2-derived NO is not only flux-dependent, which is higher in mouse vs human cells, but also varies based on spatial and temporal distribution both within tumor cells and in the tumor microenvironment NO donors have been utilized to mimic NO flux conditions and to investigate the effects of varied NO concentrations. As a wide range of effects mediated by NO and other nitrogen oxides such as nitroxyl (HNO) have been elucidated, multiple NO- and HNO-releasing compounds have been developed as potential therapeutics, including as tumor modulators. One of the challenges is to determine differences in biomarker expression from extracellular vs intracellular generation of NO or HNO. Taking advantage of new NO and HNO releasing agents, we have characterized the gene expression profile of estrogen receptor-negative human breast cancer (MDA-MB-231) cells following exposure to aspirin, the NO donor DEA/NO, the HNO donor IPA/NO and their intracellularly-activated prodrug conjugates DEA/NO-aspirin and IPA/NO-aspirin. Comparison of the gene expression profiles demonstrated that several genes were uniquely expressed with respect to NO or HNO, such as miR-21, HSP70, cystathionine gamma-lyase and IL24. These findings provide insight into targets and pathways that could be therapeutically exploited by the redox related species NO and HNO. Published by Elsevier Inc.
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland
Showing items related by title, author, creator and subject.
Low penetrance breast cancer predisposition snps are site specific Mcinerney, Niall; Colleran, Gabrielle; Rowan, Andrew; Walther, Axel; Barclay, Ella; Spain, Sarah; Jones, Angela M.; Tuohy, Stephen; Curran, Catherine; Miller, Nicola; Kerin, Michael; Tomlinson, Ian; Sawyer, Elinor (Springer Nature, 2008-11-13)Large scale association studies have identified low penetrance susceptibility alleles that predispose to breast cancer. A locus on chromosome 8q24.21 has been shown to harbour variants that predispose to breast, ovarian, ...
Sensitive surface enhanced raman scattering multiplexed detection of matrix metalloproteinase 2 and 7 cancer markers Gong, Tianxun; Kong, Kien Voon; Goh, Douglas; Olivo, Malini; Yong, Ken-Tye (The Optical Society, 2015-05-12)A surface enhanced Raman spectroscopy (SERS) based platform was developed for sensitive multiplexed detection of matrix metalloproteinases (MMP) (MMP-2 and MMP-7) with low limit of detection and high specificity. Detection ...
Systemic mirna-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease Heneghan, H. M.; Miller, N.; Kelly, R.; Newell, J.; Kerin, M. J. (Alphamed Press, 2010-06-24)Purpose. The potential of microRNAs (miRNAs) as novel tumor markers has been the focus of recent scrutiny because of their tissue specificity, stability, and association with clinicopathological parameters. Data have emerged ...